02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
00:55 , Mar 16, 2018 |  BioCentury  |  Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co....
18:50 , Mar 15, 2018 |  BC Innovations  |  Emerging Company Profile

Stabilizing damaged goods

Methuselah Health Inc. aims to treat aging-related diseases by stabilizing proteins that have adopted dysfunctional conformations as a result of genomic or environmental damage. By studying damaged proteins instead of DNA, the newco can find...
20:37 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Takeda, Zinfandel's AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial of 0.8 mg pioglitazone (AD-4833) after a planned interim futility analysis showed that the compound was inadequate...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
22:51 , Jan 25, 2018 |  BC Extra  |  Clinical News

Takeda, Zinfandel’s AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMORROW trial of 0.8 mg pioglitazone (AD-4833) SR after an interim futility analysis showed the compound was inadequate in...
21:52 , Oct 5, 2017 |  BC Innovations  |  Strategy

Fixing FDA’s FAERS

Last week FDA announced a new searchable format for its adverse events reporting database, making it easier for drug developers to use the tool to de-risk drug candidates. But according to an August publication from...
18:11 , Jun 1, 2017 |  BC Extra  |  Company News

Strekin raises CHF10 million

Strekin AG (Basel, Switzerland) raised CHF10 million ($10.3 million) in its third seed round from undisclosed private investors. The round builds on a combined CHF8.2 million ($8.4 million) Strekin had raised in seed rounds during...
20:04 , Apr 14, 2017 |  BioCentury  |  Finance

More NASH cash

Investors are hoping a $40 million A-2 round can help Cirius Therapeutics Inc. deliver the first clinical data in non-alcoholic steatohepatitis (NASH) showing a second-generation insulin sensitizer is not only efficacious, but also avoids the...
13:46 , Apr 11, 2017 |  BC Extra  |  Financial News

NASH newco Cirius raises $40M in series A

Liver company Cirius Therapeutics Inc. (Kalamazoo, Mich.) raised $40 million in a series A round led by Frazier Healthcare Partners and Novo A/S (Hellerup, Denmark). New investors Adams Street Partners and Renaissance Venture Capital Fund...